IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Sponsor: Janssen Biotech, Inc.
A PHASE2 clinical study on Prostate Cancer and Prostatic Neoplasm, this trial is completed. The trial is conducted by Janssen Biotech, Inc. and has accumulated 64 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)This is a Phase 2, prospective, multicenter, open-label, single-arm study of abiraterone acetate plus prednisone in men with non-metastatic, castration-resistant prostate cancer (CRPC) who have a rising PSA despite castrate levels of testosterone. The study consists of Screening Phase (up to 4 weeks), Core Study Treatment Phase (comprised of six 28-day cycles), a Pre-metastatic Disease Follow-up Phase, an Optional Drug Holiday Phase; and a 30-day Safety Follow-up Visit. Each treatment cycle will last 28 days. Participating participants will receive study agents (Abiraterone acetate 1000 mg/day plus prednisone 5 mg/day, orally) continually during the study. If the partcipants elects to participate in the Optional Drug Holiday Phase, participants will discontinue abiraterone acetate plus prednisone and ADT. Participants will have the option to return to study medication during the first year of the Optional Drug Holiday Phase if there is evidence of rising PSA but no metastasis based on study imaging. If participants do no elect to participate, they will continue with the core study treatment as per protocol. The study will end when all participated participants have disease progression or end of the 2-year period (if participants participated in the Optional Drug Holiday Phase). Participants will be required to return to...
This is a Phase 2, prospective, multicenter, open-label, single-arm study of abiraterone acetate plus prednisone in men with non-metastatic, castration-resistant prostate cancer (CRPC) who have a rising PSA despite castrate levels of testosterone. The study consists of Screening Phase (up to 4 weeks), Core Study Treatment Phase (comprised of six 28-day cycles), a Pre-metastatic Disease Follow-up Phase, an Optional Drug Holiday Phase; and a 30-day Safety Follow-up Visit. Each treatment cycle will last 28 days. Participating participants will receive study agents (Abiraterone acetate 1000 mg/day plus prednisone 5 mg/day, orally) continually during the study. If the partcipants elects to participate in the Optional Drug Holiday Phase, participants will discontinue abiraterone acetate plus prednisone and ADT. Participants will have the option to return to study medication during the first year of the Optional Drug Holiday Phase if there is evidence of rising PSA but no metastasis based on study imaging. If participants do no elect to participate, they will continue with the core study treatment as per protocol. The study will end when all participated participants have disease progression or end of the 2-year period (if participants participated in the Optional Drug Holiday Phase). Participants will be required to return to the study site 30 days after receiving the last dose of abiraterone acetate for safety follow-up.
Status Flow
Change History
64 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE2
-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Completed PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Completed PHASE2
▶ Show 59 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Completed PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Completed PHASE2
-
May 2025 — Jun 2025 [monthly]
Completed PHASE2
-
Apr 2025 — May 2025 [monthly]
Completed PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Jul 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Biotech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .